The aim of this study was to evaluate the ability of 4 risk-of-malignancy indexes (RMIs) to discriminate benign from malignant pelvic masses. The RMI methods were calculated for 296 patients together with the sensitivity, specificity, positive predictive value, and negative predictive value. The RMI method is a valuable and applicable method in diagnosing pelvic masses with high risk of malignancy. Background: The aim of this study was to validate the risk-of-malignancy index (RMI) incorporating menopausal status, serum CA 125 levels, and imaging findings for discriminating benign from malignant pelvic masses and to evaluate the ability of 4 different RMIs. Patients and Methods: This is a prospective study of 296 women admitted to surgical exploration of pelvic masses. The RMI 1, 2, 3, and 4 methods were calculated for all patients together with the sensitivity, specificity, positive predictive value, and negative predictive value. Results: The sensitivity of RMIs 1, 2, 3, and 4 was 73.0%, 81.1%, 73.0%, and 77.0%, respectively, and the specificity was 93.7%, 89.6%, 93.7%, and 92.3%, respectively. The RMI 2 was significantly better at predicting malignancy than RMIs 1 3; however, there was no statistically significant difference in performance of RMIs 2 4. Conclusion: The RMI method is a valuable and applicable method in diagnosing pelvic masses with high risk of malignancy and a simple technique that can be used in gynecology clinics and less-specialized centers.
Introduction
A pelvic mass is one of the most frequent indications for referral to gynecology specialists. Often, these pelvic masses are malignant and require surgical treatment. Up to 24% of ovarian tumors in premenopausal women are malignant and up to 60% are malignant in postmenopausal women. [1] [2] [3] The preoperative determination of whether a mass is malignant cannot always be made with current diagnostic modalities. Surgery can be optimally planned if it is known in advance whether an ovarian neoplasm is benign or malignant. The type of surgical procedure and the experience of the surgeon are important factors for the prognosis of ovarian cancer. An improved method for preoperative discrimination of pelvic mass would result in more women receiving first-line therapy from appropriately trained and experienced personnel. 4, 5 For such referrals to be efficient, improved specific and sensitive methods for diagnosing ovarian cancer are needed.
Used alone, the diagnostic accuracy of demographics, ultrasound (US), and biochemical variables is inadequate for clinical application. Various combined methods for evaluating the risk of ovarian cancer have been proposed. The riskof-malignancy index (RMI) is a simple scoring method based on menopausal status, US findings, and the serum CA 125 level. This method has given significantly better results than the use of a single parameter. [6] [7] [8] The RMI can be applied in less-specialized centers. The RMI is the product of the imaging scores (U), the menopausal score (M), and the absolute value of the serum CA 125:
In 1990, Jacobs et al 6 originally developed the RMI, which we have termed "RMI 1." Tingulstad et al 7 developed their version of the RMI in 1996, and it is known as RMI 2. In1999, Tingulstad et al 8 modified the RMI, which we have termed "RMI 3." In 2009, Yamamoto et al 9 added the parameter of the tumor size score (S) to the RMI and have termed it the RMI 4:
The aim of this study was to evaluate the ability of 4 RMI to discriminate a benign from a malignant pelvic mass and to evaluate the performances of 4 RMI.
Patients and Methods
This is a prospective study. The clinical data were obtained from 296 women with a pelvic mass scheduled for laparotomy and laparoscopy at the Department of Obstetrics and Gynecology of Kochi Health Sciences Center between September 1, 2011, and April 30, 2014. Preoperative serum CA 125 levels, imaging findings, and menopausal status were noted. All patients were required to have a pelvic US, computed tomography (CT), magnetic resonance imaging (MRI), or any combination of imaging modalities for documentation of an ovarian tumor or a pelvic mass. An RMI imaging score was assigned for the following features suggestive of malignancy: the presence of a multilocular cystic lesion; solid areas; bilateral lesions; ascites; and intraabdominal metastases. One point was given for each feature. A total imaging score (U) was calculated for each patient, and the tumor size (S) was measured by US, CT, and/or MRI for each patient. Postmenopausal status was defined as more than 1 year of amenorrhea or age greater than 50 years in women who had undergone hysterectomy. All other women were considered premenopausal. Preoperative serum CA 125 levels were measured in the hospital's biochemistry laboratory by ECLusys CA125 II assay (Roche Diagnostics, Tokyo, Japan).
On the basis of the data obtained, the RMI 1, 2, 3, and 4 methods were calculated for all patients together with the sensitivity, specificity, positive predictive value, and negative predictive value of the 4 methods: The histopathologic diagnosis was regarded as the definite outcome. When a gynecological cancer was found, it was staged according to the International Federation of Gynecology and Obstetrics (FIGO) classification. 10 The sensitivity was defined as the percentage of patients with malignant disease having a positive test result. The specificity was defined as the percentage of patients with benign disease having a negative test result. The positive predictive value was defined as the percentage of patients with a positive test result having malignant disease and the negative predictive value was defined as the percentage of patients with a negative test result having benign disease. The c 2 test was used to test differences in distribution of age, menopausal status, imaging score, and tumor size. The Mann-Whitney U test was applied when testing differences in distribution of CA 125 among women with benign and malignant pelvic masses. The McNemar test was used when testing differences in performances between RMIs 1, 2, 3, and 4.
Results
Of 296 patients, 74 (25.0%) had malignant disease and 222 (75.0%) had benign pathology. The mean age of the patients with malignant disease was 56.3 AE 15.7 years, and in those with benign pathology, it was 43.6 AE 15.4 years. The histopathologic classification of benign cases and FIGO 10 stages of malignant cases were detailed in Table 1 . 
Comparison of 4 RMIs
The distribution of benign and malignant cases by age, menopausal status, imaging score, and tumor size is described in Table 2 . In univariate analysis, a significant linear trend for malignancy was found by increasing age, increasing imaging score, and increasing tumor size. Significantly, more postmenopausal than premenopausal women had malignant disease. The mean serum level of CA 125 was significantly higher among women with malignancy when compared with women who suffered from a benign pelvic mass. The performance of RMIs 1, 2, 3, and 4 was presented in Table 3 . A direct comparison of the 4 indexes showed that RMI 2 was significantly better at predicting malignancy than RMIs 1 and 3 (P ¼ .04). There was no statistically significant difference in performance of RMIs 2 and 4. Because the purpose of initial evaluation of the patients by RMI was to ensure referral of patients with advance ovarian cancer, the results were analyzed considering stage I disease a "benign" disease. The results of the performance of RMIs 1, 2, 3, and 4 were presented in Table 4 .
The false-positive and false-negative cases were listed in Table 5 . Up to 40% of the false-positive cases were endometriosis. The false-negative cases were primarily borderline ovarian tumors and stage I invasive ovarian cancers.
Discussion
This study has confirmed the ability of 4 RMIs (RMIs 1, 2, 3, and 4) to accurately discriminate between malignant and benign pelvic masses. The RMI was originally developed by Jacobs et al, 6 and subsequently, the same group reproduced the results in a second patient population, establishing the superiority of the RMI over the use of an individual parameter. 11 Many authors suggest that the best cutoff value for RMIs 1, 2, and 3 is 200. [6] [7] [8] 12, 13 The best cutoff value for RMI 4 is 450. 9 The sensitivity of RMIs 1, 2, 3, and 4 was 73.0%, 81.1%, 73.0%, and 77.0%, respectively. The specificity of RMIs 1, 2, 3, and 4 was 93.7%, 89.6%, 93.7%, and 92.3%, respectively. These are in accordance with the results of other studies. [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] A direct comparison of the 4 indexes showed that RMI 2 was significantly better at predicting malignancy than RMIs 1 and 3 (P ¼ .04); however, there was no statistically significant difference in performance of RMIs 2 and 4. The primary purpose of initial evaluation of the patients by RMI was to ensure referral of patients with advance ovarian cancer (greater than stage II) for primary surgery at the gynecologic oncologic center. Our results demonstrated that up to 95% were correctly identified before treatment by RMIs 2 or 4 in Table 4 . Otherwise, our results demonstrated the limitation of RMI in identifying patients with primarily borderline ovarian tumors and stage I invasive ovarian cancers in Table 5 .
In conclusion, the RMI is a simple scoring system, which can be used in daily clinical practice in nonspecialized gynecologic 
Clinical Practice Points
This study has confirmed the ability of four malignancy risk indices (RMI 1, RMI 2, RMI 3, and RMI 4) to accurately discriminate between malignant and benign pelvic masses. The RMI is a simple scoring system which can be used in daily clinical practice by all gynecologists. No problems with application of the method were observed in the participating departments. This study has confirmed that an RMI can be a valuable and applicable method in diagnosing pelvic masses with high risk of malignancy, and is a workable method for appropriate and timely referral of patients for specialized surgical treatment. It is our impression that the use of an RMI has resulted in improved preoperative planning from referral to actual performance of surgery, as well as the planning of the surgical approach (laparoscopy versus laparotomy, and transverse abdominal versus median abdominal incision). Otherwise, this study results demonstrate the limitations of RMI in identifying patients with primarily borderline ovarian tumors and stage I invasive ovarian cancers. Many cases of primarily borderline ovarian tumors and stage I invasive ovarian cancers were false-negative. Other models of preoperative evaluation should be developed in order to improve the detection of borderline pelvic masses and ovarian tumors, and detection of stage I invasive ovarian cancers.
